Trial Profile
A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; Eisai Co Ltd
- 24 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2010 Planned end date changed from 1 Oct 2011 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 14 Oct 2009 Actual patient number (41) added as reported by ClinicalTrials.gov.